WARSAW, Ind., October 31, 2018 – Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced Ivan Tornos, previously Worldwide President for Urology/Medical and Critical Care at Becton, Dickinson and Company (NYSE: BDX), will join Zimmer Biomet as Group President, Orthopedics, effective November 1, 2018.
“Ivan is a great addition to our leadership team, bringing deep medical technology expertise and a strong history of successfully managing complex businesses across several continents,” said Bryan Hanson, President and CEO of Zimmer Biomet. “Ivan’s exceptional track record of executing on commercial strategies and driving growth and profitability will be critical to Zimmer Biomet as we continue our focus on achieving sustained performance in the business.”
Mr. Tornos comes to Zimmer Biomet having served for more than two decades in various global roles for Fortune 50 to 500 companies. In this newly created position, Mr. Tornos will be responsible for increased innovation, implementation and execution of the Orthopedics group, which will include our large joint, sports, extremities and trauma (S.E.T.) businesses as well as our Americas region.
About Ivan Tornos
Prior to joining Zimmer Biomet, Mr. Tornos served as Worldwide President of the Global Urology/Medical and Critical Care Division of Becton, Dickinson and Company. Prior to that, he was with C.R. Bard, most recently serving as President, Europe, Middle East and Africa Regions. Before joining C.R. Bard, Mr. Tornos served as Vice President and General Manager of the Americas Pharmaceutical and Medical/Imaging Segments of Covidien International. Before that, Mr. Tornos served as International Vice President, Business Development and Strategy with Baxter International Inc. and prior to that, he spent 11 years with Johnson & Johnson in positions of increasing responsibility.
Mr. Tornos is an alumnus of the Harvard Business School having graduated from the Advanced Management Program (AMP 187) and also completed Leadership and Management programs at the Cox School of Business of Southern Methodist University. He finalized post-MBA work at the Wharton School of the University of Pennsylvania (CPD Marketing/Finance), holds an MBA from the University of Miami School of Business and a BBA in Finance and International Marketing and Management from the University of Georgia Terry College of Business.
About Zimmer Biomet
Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet is a global leader in musculoskeletal healthcare. We design, manufacture and market orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants; and related surgical products.
We collaborate with healthcare professionals around the globe to advance the pace of innovation. Our products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Together with healthcare professionals, we help millions of people live better lives.
We have operations in more than 25 countries around the world and sell products in more than 100 countries. For more information, visit www.zimmerbiomet.com.
Cautionary Statement Regarding Forward-Looking Statements
This release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning Zimmer Biomet’s expectations, plans, prospects, and product and service offerings, including new product launches and potential clinical successes. Such statements are based upon the current beliefs and expectations of management and are subject to significant risks, uncertainties and changes in circumstances that could cause actual outcomes and results to differ materially. For a list and description of some of such risks and uncertainties, see Zimmer Biomet’s periodic reports filed with the U.S. Securities and Exchange Commission (SEC). These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Zimmer Biomet’s filings with the SEC. Forward-looking statements speak only as of the date made. Zimmer Biomet disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers of this release are cautioned not to rely on these forward-looking statements, since there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this release.
Contacts:
Media
Monica Kendrick
574-372-4989
monica.kendrick@zimmerbiomet.com
Investors
Coleman Lannum
574-371-9480
cole.lannum@zimmerbiomet.com
Derek Davis
574-372-4250
derek.davis@zimmerbiomet.com
